ArticleHaematologica2023
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications.
Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 53 citations in OpenAlex.
- Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms.Blood advances · 2026Article
- Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.American journal of hematology · 2026Article
- Therapy-related myeloid neoplasms following treatment for high-risk gestational trophoblastic neoplasia: a case series and retrospective analysis.International journal of clinical oncology · 2026Article
- Can Disruption of Circadian Rhythms Be Linked to Radiation-Induced Acute Myeloid Leukaemia?Cancers · 2026Review
- Validation of ICC hierarchical classification in secondary AML.Blood advances · 2026Article
- Venetoclax-based combination regimens for therapy-related myeloid neoplasms.International journal of hematology · 2026Article
- Targeting LAPTM5 enhances AML sensitivity to cytarabine through autophagy inhibition.Cell death & disease · 2026Article
- Impact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant-Eligible and Ineligible Acute Myeloid Leukemia.Cancer medicine · 2026Article
- Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies.HemaSphere · 2026Article
- Concurrent therapy-related acute myeloid leukemia and lymph node tuberculosis following treatment for lung squamous cell carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Comprehensive analysis of the potential effect and mechanism of pyroptosis-related genes in treatment-related myeloid tumors.PloS one · 2026Article
- The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China.Science China. Life sciences · 2026Article
- PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.ESMO open · 2025Article
- Global, regional and national epidemiology of acute myeloid leukemia (1990-2021): a statistical analysis of incidence, mortality, and DALYs.Annals of medicine · 2025Article
- Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments.Journal of internal medicine · 2025Review
- Article
- On the road to improved therapies for therapy-related AML.Blood advances · 2025Article
- Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations.Blood advances · 2025Article
- Impact of primary cancer history and molecular landscape in therapy-related myeloid neoplasms.Frontiers in oncology · 2025Article
- Recent advances in AML with mutated NPM1.International journal of hematology · 2024Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized, defined the incidence over time and studied prognostic implications in all t-AML patients diagnosed in Sweden between 1997 and 2015. Data were retrieved from nationwide population-based registries. In total, 6,779 AML patients were included in the study, of whom 686 (10%) had t-AML. The median age for t-AML was 71 years and 392 (57%) patients were females. During the study period, the incidence of t-AML almost doubled with a yearly increase in t-AML of 4.5% (95% confidence interval: 2.8%-6.2%), which contributed significantly to the general increase in AML incidence over the study period. t-AML solidly constituted over 10% of all AML cases during the later period of the study. Primary diagnoses with the largest increase in incidence and decrease in mortality rate during the study period (i.e., breast and prostate cancer) contributed significantly to the increased incidence of t-AML. In multivariable analysis, t-AML was associated with poorer outcome in cytogenetically intermediate- and adverse-risk cases but t-AML had no significant impact on outcome in favorable-risk AML, including core binding leukemias, acute promyelocytic leukemia and AML with mutated NPM1 without FLT3-ITD. We conclude that there is a strong increase in incidence in t-AML over time and that t-AML constitutes a successively larger proportion of the AML cases. Furthermore, we conclude that t-AML confers a poor prognosis in cytogenetically intermediate- and adverse-risk, but not in favorable-risk AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.